CN104812756A - 多激酶通路抑制剂 - Google Patents

多激酶通路抑制剂 Download PDF

Info

Publication number
CN104812756A
CN104812756A CN201380060317.8A CN201380060317A CN104812756A CN 104812756 A CN104812756 A CN 104812756A CN 201380060317 A CN201380060317 A CN 201380060317A CN 104812756 A CN104812756 A CN 104812756A
Authority
CN
China
Prior art keywords
dialkylamino
compound
alkyl
acceptable salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380060317.8A
Other languages
English (en)
Chinese (zh)
Inventor
Q.曾
M.法里斯
A.莫拉德
S.L.沃纳
G.A.弗林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tuo Leluo Medicine Limited-Liability Co
Man Kaide Co
Original Assignee
Tuo Leluo Medicine Limited-Liability Co
Man Kaide Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuo Leluo Medicine Limited-Liability Co, Man Kaide Co filed Critical Tuo Leluo Medicine Limited-Liability Co
Publication of CN104812756A publication Critical patent/CN104812756A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380060317.8A 2012-09-26 2013-09-25 多激酶通路抑制剂 Pending CN104812756A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261706084P 2012-09-26 2012-09-26
US61/706,084 2012-09-26
US201361757331P 2013-01-28 2013-01-28
US61/757,331 2013-01-28
US201361785992P 2013-03-14 2013-03-14
US61/785,992 2013-03-14
PCT/US2013/061548 WO2014052365A1 (en) 2012-09-26 2013-09-25 Multiple kinase pathway inhibitors

Publications (1)

Publication Number Publication Date
CN104812756A true CN104812756A (zh) 2015-07-29

Family

ID=50388917

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380060317.8A Pending CN104812756A (zh) 2012-09-26 2013-09-25 多激酶通路抑制剂

Country Status (8)

Country Link
US (2) US9493454B2 (enExample)
EP (1) EP2900668A4 (enExample)
JP (1) JP2015532281A (enExample)
CN (1) CN104812756A (enExample)
AU (1) AU2013323736A1 (enExample)
CA (1) CA2886275A1 (enExample)
HK (1) HK1212683A1 (enExample)
WO (1) WO2014052365A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105130986A (zh) * 2015-09-30 2015-12-09 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
WO2018108167A1 (zh) * 2016-12-16 2018-06-21 基石药业 Cdk4/6抑制剂
CN108264511A (zh) * 2017-01-03 2018-07-10 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和其在医药上的用途
WO2024012543A1 (zh) * 2022-07-14 2024-01-18 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3409278B8 (en) 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
AU2013323736A1 (en) * 2012-09-26 2015-04-09 Mannkind Corporation Multiple kinase pathway inhibitors
US10202356B2 (en) 2013-03-14 2019-02-12 Tolero Pharmaceuticals, Inc. JAK2 and ALK2 inhibitors and methods for their use
CN104418853B (zh) * 2013-08-28 2016-09-07 北大方正集团有限公司 取代的萘啶-2-酮化合物、制备方法、用途及药物组合物
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
WO2016161248A1 (en) * 2015-04-02 2016-10-06 Tolero Pharmaceuticals, Inc. Targeting pim kinases in combination with btk inhibition
EP4086264B1 (en) 2015-05-18 2023-10-25 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
CA2993659A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018213219A1 (en) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
CA3096984A1 (en) 2018-04-05 2019-10-10 Sumitomo Dainippon Pharma Oncology, Inc. Axl kinase inhibitors and use of the same
US20210113562A1 (en) 2018-04-13 2021-04-22 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
CA3119807A1 (en) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2022510410A (ja) * 2018-12-07 2022-01-26 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 去勢抵抗性および去勢感受性前立腺がんを処置するための方法
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150359A (en) * 1997-08-20 2000-11-21 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
US20030144351A1 (en) * 1998-08-21 2003-07-31 Parker Hughes Institute BTK inhibitors and methods for their identification and use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
CA2542105C (en) 2003-10-08 2011-08-02 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2009537520A (ja) 2006-05-15 2009-10-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｆｇｆ受容体キナーゼ阻害剤のための組成物および方法
US8604031B2 (en) 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
AU2013323736A1 (en) * 2012-09-26 2015-04-09 Mannkind Corporation Multiple kinase pathway inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150359A (en) * 1997-08-20 2000-11-21 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
US20030144351A1 (en) * 1998-08-21 2003-07-31 Parker Hughes Institute BTK inhibitors and methods for their identification and use

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018534352A (ja) * 2015-09-30 2018-11-22 グアンジョウ ベベター メディシン テクノロジー カンパニー リミテッド ピリミジン又はピリドピロドン類化合物、及びその応用
WO2017054484A1 (zh) * 2015-09-30 2017-04-06 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
CN105130986A (zh) * 2015-09-30 2015-12-09 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
US10183941B2 (en) * 2015-09-30 2019-01-22 Guangzhou Bebetter Medicine Technology Co., Ltd. Pyrimidine or pyridopyridone compound and application thereof
AU2016333188B2 (en) * 2015-09-30 2018-10-25 Bebetter Med Inc. Pyrimidine or pyridopyridone compound and application thereof
US10676474B2 (en) 2016-12-16 2020-06-09 Cstone Pharmaceuticals 1,6-naphthyridine derivatives as CDK4/6 inhibitor
KR20190092549A (ko) * 2016-12-16 2019-08-07 씨스톤 파마슈티컬즈 Cdk4/6 억제제
CN110382495A (zh) * 2016-12-16 2019-10-25 基石药业 Cdk4/6抑制剂
WO2018108167A1 (zh) * 2016-12-16 2018-06-21 基石药业 Cdk4/6抑制剂
TWI749126B (zh) * 2016-12-16 2021-12-11 大陸商基石藥業（蘇州）有限公司 Cdk4/6抑制劑
CN110382495B (zh) * 2016-12-16 2022-04-05 基石药业（苏州）有限公司 Cdk4/6抑制剂
KR102513448B1 (ko) 2016-12-16 2023-03-23 씨스톤 파마슈티컬즈 Cdk4/6 억제제
CN108264511A (zh) * 2017-01-03 2018-07-10 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和其在医药上的用途
CN108264511B (zh) * 2017-01-03 2021-04-13 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和其在医药上的用途
WO2024012543A1 (zh) * 2022-07-14 2024-01-18 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用

Also Published As

Publication number Publication date
AU2013323736A8 (en) 2015-04-30
US20170107215A1 (en) 2017-04-20
AU2013323736A1 (en) 2015-04-09
WO2014052365A1 (en) 2014-04-03
US9493454B2 (en) 2016-11-15
US9714247B2 (en) 2017-07-25
CA2886275A1 (en) 2014-04-03
EP2900668A4 (en) 2016-04-20
US20150266870A1 (en) 2015-09-24
JP2015532281A (ja) 2015-11-09
EP2900668A1 (en) 2015-08-05
HK1212683A1 (zh) 2016-06-17

Similar Documents

Publication Publication Date Title
CN104812756A (zh) 多激酶通路抑制剂
JP6475158B2 (ja) Ｍｎｋ１およびｍｎｋ２調節剤としての二環式ヘテロアリール誘導体、およびその使用
JP7373992B2 (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
CN102203093B (zh) 氨基三唑并吡啶和其作为激酶抑制剂的用途
CN101952287B (zh) 蛋白激酶抑制剂及其应用
RU2569635C9 (ru) ЗАМЕЩЕННЫЕ ПИРИДОПИРАЗИНЫ КАК НОВЫЕ ИНГИБИТОРЫ Syk
WO2018153373A1 (zh) Fgfr抑制剂及其应用
CN112601752A (zh) Map4k1的新颖抑制剂
RS61919B1 (sr) Inhibitori hpk1 i postupci za njihovo korišćenje
CN102361859A (zh) 用作Raf激酶抑制剂的杂芳基化合物
KR101921764B1 (ko) 피라졸로-퀴놀린
CA3106961A1 (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
CN102137866A (zh) 羟吲哚化合物
WO2015050505A1 (en) Bicyclic alkyne derivatives and uses thereof
JP2022518723A (ja) ピロロピリジン誘導体およびタンパク質キナーゼ関連疾患の予防または治療での使用のためのその用途
EP4358954A1 (en) Cdk2 inhibitors and methods of using the same
CN111153891A (zh) 一种取代苯并咪唑类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
CN117730083A (zh) 用作map4k1抑制剂的嘧啶化合物
RU2807277C2 (ru) Соединения пиримидина и содержащие их фармацевтические композиции для предупреждения или лечения рака
TWI759829B (zh) 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
JP2025536323A (ja) 縮合二環式化合物ならびにＭｅｒ阻害剤およびＡｘｌ阻害剤としてのその使用
HK40009843A (en) Fgfr inhibitor and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150729